Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
Volume 2.23M
Average 1.99M
MIST Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Milestone Pharmaceuticals Inc.NASDAQ: MIST
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $3.36M fell 32.5% year over year, behind the +5.5% change in trailing-twelve-month research & development. Sequentially, it fell 39.1% from the prior quarter. Over 3 fiscal years it compounded at -23.1% a year.
Context
- Research & development amounted to 1171.3% of revenue in FY2025.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -32.5% toward the trailing-twelve-month pace of +5.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 18.11M USD
- Year-over-year change
- +26.1%
- 4-year CAGR
- -17.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.11M | +26.1% |
| FY2024 | 2024-12-31 | 14.36M | -53.8% |
| FY2023 | 2023-12-31 | 31.05M | -22.0% |
| FY2022 | 2022-12-31 | 39.83M | +3.0% |
| FY2021 | 2021-12-31 | 38.67M | — |
Research & Development vs competitors
How MIST compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.5% is the 2nd highest of 8, against a peer median of -19.6%.
- Research & development amounts to 928.4% of revenue for MIST, versus a peer median of 1565.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $74.27M USD | +76.4% | +63.2% | — | |
| LTM Mar 2026 | $58.35M USD | -32.7% | +9.5% | — | |
| LTM Mar 2026 | CHF 46.97M CHF | -1.7% | -7.5% | — | |
| FY2025 | €43.62M EUR | -16.1% | -5.5% | 1565.1% | |
| LTM Mar 2026 | $31.62M USD | -19.6% | +9.2% | 6022.3% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $23.84M USD | -29.5% | +13.5% | — |
| LTM Mar 2026 | $18.8M USD | -26.8% | -18.0% | 593.1% | |
| LTM Mar 2026 | $16.56M USD | +5.5% | -23.1% | 928.4% | |
| Peer median (excluding MIST) | — | -19.6% | +9.2% | 1565.1% | |
Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 15M | 5M | 1M | 0 | 1.55M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 114K |
| Gross Profit | 15M | 5M | 1M | 0 | 1.43M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 92.6% |
| Research & Development | 38.67M | 39.83M | 31.05M | 14.36M | 18.11M |
| Selling, General & Admin | 19.4M | 24.81M | 31.05M | 27.75M | 17.27M |
| Operating Expenses | 58.07M | 64.64M | 62.1M | 42.1M | 63.92M |
| Depreciation & Amortization | 93K | 89K | 92K | 105K | 114K |
| EBITDA | (42.76M) | (58.3M) | (57.04M) | (37.83M) | (59.45M) |
| EBITDA Margin | -285.1% | -1166.0% | -5703.9% | — | -3845.5% |
| Operating Income | (43.07M) | (59.64M) | (61.1M) | (42.1M) | (62.49M) |
| Operating Margin | -287.2% | -1192.8% | -6109.8% | — | -4041.7% |
| Interest Income | 220K | 1.25M | 3.97M | 4.16M | 2.92M |
| Interest Expense | 0 | 0 | 2.55M | (3.58M) | 3.84M |
| Other Income / Expenses | 220K | 1.25M | 1.41M | 583K | (918K) |
| Income Before Tax | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.4M) |
| Pre-Tax Margin | -285.7% | -1167.8% | -5968.5% | — | -4101.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | (345K) |
| Net Income | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.06M) |
| Net Margin | -285.7% | -1167.8% | -5968.5% | — | -4078.8% |
| EPS (Basic) | (1.02) | (1.35) | (1.39) | (0.67) | (0.75) |
| EPS (Diluted) | (1.02) | (1.35) | (1.39) | (0.67) | (0.75) |
| Weighted Avg Shares | 41.83M | 42.45M | 42.96M | 62.21M | 83.88M |
| Weighted Avg Shares (Diluted) | 41.83M | 42.45M | 42.96M | 62.21M | 83.88M |
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
Intrinsic Alpha fair value
Locked
Current Price
$0.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.